262 related articles for article (PubMed ID: 25502954)
1. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
Solomon C; Gröner A; Ye J; Pendrak I
Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
[TBL] [Abstract][Full Text] [Related]
2. Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data.
Solomon C; Korte W; Fries D; Pendrak I; Joch C; Gröner A; Birschmann I
Transfus Med Hemother; 2016 Sep; 43(5):365-373. PubMed ID: 27781024
[TBL] [Abstract][Full Text] [Related]
3. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.
Kouides P; Wawra-Hehenberger K; Sajan A; Mead H; Simon T
Transfusion; 2017 Oct; 57(10):2390-2403. PubMed ID: 28691218
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety Analysis of a Fibrinogen Concentrate (RiaSTAP
Rahe-Meyer N; Neumann G; Schmidt DS; Downey LA
Clin Appl Thromb Hemost; 2024; 30():10760296241254106. PubMed ID: 38803191
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of etifoxine: A French pharmacovigilance survey.
Cottin J; Gouraud A; Jean-Pastor MJ; Dautriche AD; Boulay C; Geniaux H; Auffret M; Bernard N; Descotes J; Vial T
Fundam Clin Pharmacol; 2016 Apr; 30(2):147-52. PubMed ID: 26588183
[TBL] [Abstract][Full Text] [Related]
6. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions to self-medication: a study in a pharmacovigilance database.
Berreni A; Montastruc F; Bondon-Guitton E; Rousseau V; Abadie D; Durrieu G; Chebane L; Giroud JP; Bagheri H; Montastruc JL
Fundam Clin Pharmacol; 2015 Oct; 29(5):517-20. PubMed ID: 26215671
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
[TBL] [Abstract][Full Text] [Related]
9. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review.
Iammatteo M; Blumenthal KG; Saff R; Long AA; Banerji A
J Allergy Clin Immunol Pract; 2014; 2(6):768-74. PubMed ID: 25439369
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
11. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
[TBL] [Abstract][Full Text] [Related]
12. Perioperative administration of fibrinogen does not increase adverse cardiac and thromboembolic events after cardiac surgery.
Fassl J; Lurati Buse G; Filipovic M; Reuthebuch O; Hampl K; Seeberger MD; Bolliger D
Br J Anaesth; 2015 Feb; 114(2):225-34. PubMed ID: 25324348
[TBL] [Abstract][Full Text] [Related]
13. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
Shalviri G; Yousefian S; Gholami K
J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
[TBL] [Abstract][Full Text] [Related]
14. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions: Part I.
Wooten JM
South Med J; 2010 Oct; 103(10):1025-8; quiz 1029. PubMed ID: 20818299
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug reactions to anthroposophic and homeopathic solutions for injection: a systematic evaluation of German pharmacovigilance databases.
Jong MC; Jong MU; Baars EW
Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1295-301. PubMed ID: 22692862
[TBL] [Abstract][Full Text] [Related]
18. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
19. [Study of analysis 1 390 adverse drug reactions cases of parenterally administered dengzhan xixin based on China's spontaneous response system].
Li YY; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2998-3002. PubMed ID: 24471319
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacovigilance of parenterally administered salvianolate based on analysis of spontaneous reporting system data].
Lu PF; Xiang YY; Xie YM; Chang YP; Wang ZG
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3003-7. PubMed ID: 24471320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
